3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy.  3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments. 

<p>3T Biosciences is identifying novel targets for the treatment of solid tumors and other immune-mediated diseases. Current treatment options for solid tumors often have limited or negligible efficacy.  3T is understanding how the immune system recognises, targets and destroys cancer cells to develop novel immunotherapies. To develop immunotherapies, 3T is using their proprietary, novel technology called 3T-TRACE (T cell receptor antigen and cross-reactivity engine) to identify novel targets and therapeutically active T cell receptors (TCRs) and TCR mimetics (TCRm). 3T-TRACE employs machine learning and high-diversity target libraries to create highly specific, safe and more effective cancer treatments. </p>


3T Biosciences

As the year draws to a close, we at 3T Biosciences would like to extend our warmest wishes for a joyful holiday season. We are grateful for the support of our partners, collaborators, and community as we work towards advancing therapies for solid tumors. 

#Biotech #Biopharma #Oncology

 Marina T Alamanou, PhD on LinkedIn: #science #health #drugdevelopment #drugdiscovery #ai #biotech… 

At 3T Biosciences, we are dedicated to advancing therapies for solid tumors. Our CEO, Stefan J. Scherer M.D., Ph.D., emphasizes, “3T’s TRACE technology, short for T-Cell Receptor Antigen and Cross-Reactivity Engine, enables us to address one of the biggest challenges in cancer treatment – to identify novel targets and to develop next-generation therapies for solid tumors and other immune-mediated diseases with curative potential.” 

Follow us on LinkedIn as we strive to make a difference in oncology.


We are excited to share groundbreaking research from our Chief Development Officer Estelle Marrer-Berger, Ph.D., that was recently published in Nature Communications.

The study, based on research conducted while at Roche, sheds light on the intricate interplay between novel TCR-like antibody therapeutics and human tissue environments, unlocking crucial insights that pave the way for enhanced efficacy and safety in therapeutic interventions.

You can read Estelle’s paper, titled “The physiological interactome of TCR-like antibody therapeutics in human tissues,” here: https://lnkd.in/eSGfSV78

Huge congratulations to Dr. Marrer-Berger and the entire team for this remarkable achievement! This reinforces 3 T’s commitment to using great science to develop immunotherapies that dramatically improve treatments for patients in need.

#BioTech #Immunotherapy #Roche #NatureCommunications

3T Biosciences Expands Leadership Team With Bryan Irving, Ph.D., as Chief Scientific Officer to Progress Tumor-specific Therapies to Clinic - PR Newswire

Novel T cell receptor-based solid tumor therapies - Nature.com

Backed by $40M, a biotech startup targets cancer with help from the immune system - BioPharma Dive

Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform - Fierce Biotech


              Emory University announces recipients of the first Max Cooper Prize in Immunology | Emory University | Atlanta GA
            

Next-generation cancer therapies based on T cell receptors

We're hiring: https://lnkd.in/g_ECZWJj

#proteinsciences #scientistII #seniorscientist

Facile method for screening clinical T cell receptors for off-target peptide-HLA reactivity

Silicon Valley Billionaires are Quietly Backing This Stealth Immunotherapy Startup - BioSpace

Isolation of a Structural Mechanism for Uncoupling T Cell Receptor Signaling from Peptide-MHC Binding

3T Biosciences 27-Slide Pitch Deck to Raise $40M Series a - Business Insider

Identification of Antigenic Targets

 Boehringer strikes deals with Ribo, 3T Biosciences with combined $2.5B value 

Westlake backs 3T to use Stanford tech to land one-two punch on TCR challenges - Fierce Biotech

 Boehringer and 3T Biosciences enter second partnership 

We’re pleased to announce Jonathan MacQuitty to 3T’s Board of Directors, effective immediately. Jonathan is a highly respected business leader and venture partner, bringing with him a wealth of expertise in life science and healthcare. He is a Partner for Life Sciences at Lightspeed Venture Partners. Learn more about our newest board member: https://lnkd.in/gfeS_cPj

#BioPharma
#Biotechnology
#LifeSciences

 Boehringer offers 3T Biosciences $268M to plug its data into biotech's TCR cancer platform 

Boehringer double dips at 3T, inking second T-cell anticancer deal to swell potential payday to $538.5M - Fierce Biotech


              Scientist II/Senior Scientist – Protein Sciences
            

Our 3T-TRACE platform - short for T-Cell Receptor Antigen and Cross-Reactivity Engine - is central to our mission of identifying highly specific and immunogenic targets in solid tumors. By leveraging machine learning and diverse target libraries, we aim to create safer and more effective treatments for cancer patients. 

Discover how we are reshaping the landscape of cancer therapy with 3T-TRACE: https://lnkd.in/g-Y9FQbD

#CancerResearch #3TBiosciences #Immunotherapy #OncologyInnovation #TargetedTherapies


 Boehringer–3T Biosciences: cancer immunotherapies, 202301– strategic collab + license agreem RnD of cancer therapies using 3T-TRACE discovery platform 

 3T Biosciences Launches $40M at Solid Tumors with TCR Tech 


              Christopher Garcia is the 2024 Passano Award winner
            

3T Biosciences Builds Transatlantic Pan-Cancer Research Pipeline to Target Most Difficult-to-Treat Cancers - PR Newswire

3T Biosciences Launches $40M at Solid Tumors with TCR Tech - BioSpace

 Boehringer double dips at 3T, inking second T-cell anticancer deal to swell potential payday to $538.5M 

 3T Biosciences Builds Transatlantic Pan-Cancer Research Pipeline to Target Most Difficult-to-Treat Cancers 

 Boehringer, 3T Biosciences to develop cancer immunotherapies 

Boehringer Ingelheim and 3T Biosciences enter into a second partnership to develop next-generation cancer immunotherapies - PR Newswire

Boehringer Ingelheim, 3T Biosciences enter into second partnership for cancer immunotherapies - Medical Dialogues

3T Biosciences Debuts with $40 Million Series A Financing - PR Newswire

Peter Thiel and Sean Parker are financing a secretive cancer-fighting start-up, source says - CNBC

Boehringer offers $268M to plug data into 3T's cancer ...

Intracellular targets as source for cleaner targets for the treatment of solid tumors

At 3T, our commitment to patients drives every aspect of our work. 

We harness the power of machine learning to gain insights into how patients' immune systems recognize, target, and eliminate cancer cells. By analyzing samples from patients who have responded to immuno-oncology therapies, we aim to deepen our understanding of the immune system's response to cancer and identify novel T-cell receptor targets that are both prevalent and immunogenic. Our goal? To develop next-generation therapies that are not only safer and more effective but also hold the potential for curative outcomes in challenging cancers.

Stay tuned to learn more about our approaches to precision oncology and how we’re changing the landscape of cancer treatment. Together, we can make a difference!  

#PrecisionOncology #3TBiosciences #Immunotherapy

3T Biosciences

Business:

Drug notes:

About: